Plain-English translation of NCT06769295 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called , which works in two ways at once to fight cancer cells and stop new blood vessels from feeding tumors. It's being combined with standard chemotherapy drugs to treat advanced non-small cell lung cancer, specifically in patients who also have fluid buildup around their lungs—a complication that can make breathing harder.
Advanced lung cancer with fluid around the lungs is a serious condition that needs better treatment options. This trial is exploring whether combining this medication with chemotherapy can help control the cancer more effectively and improve outcomes for these patients.
You likely qualify if…
You likely don't qualify if…
You would receive the medication combined with chemotherapy drugs (Pemetrexed or Taxol plus Carboplatin or Cisplatin) through an injection on the first day of each 3-week cycle for 4 cycles. After those 4 cycles, you would continue receiving the medication alone until your cancer stops responding. Throughout the trial, you'll have regular visits for blood tests, imaging scans, and checkups to monitor how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China